The therapy, Living Well, is a CE-certified application that delivers sessions about regulating emotions, cognitive work with negative thoughts, and planning and behavioral activation. Users can also complete exercises, covering subjects such as mindfulness and gratitude, and emotion and stress tests.
Through the app, Prosoma hopes to improve patients’ quality of life and reduce the stress, anxiety, and depression associated with cancer diagnosis. The app is already reimbursed by healthcare insurance companies in Germany but work to get the costs covered in other markets, notably the US, is ongoing.
Prosoma has brought the service provider Eversana on board to support commercialization. Ed Cox, SVP global strategic accounts and head of digital medicine at Eversana, explained the role his company will play in the process.
“Eversana’s digital therapeutics and overall commercialization teams are working closely with Prosoma to navigate the complexities of launch and commercialization strategies for Living Well. It can be particularly challenging to educate regulatory bodies, payers, clinicians, and even patients on the benefits of a digital therapy like Living Well.
“We are finalizing what these plans look like in the coming months and are hopeful and confident we can help Prosoma bring this important therapy to cancer patients soon,” said Cox.
Eversana landed the Prosoma contract after building what Cox calls a “truly integrated commercialization platform that can bring speed and quality to any product launch.” The platform, and the expertise and experience that surrounds it, enabled Eversana to win the contract.
“Our team of experts are seasoned digital therapeutics veterans who have built, secured regulatory milestones, funded, partnered, and launched a variety of digital health products via various commercial models. This, coupled with our commitment to helping patients have better outcomes made us a great fit for the Prosoma team,” said Cox.
